Part of UNIVERSITY OF MICHIGAN
Clinical Trials
320
28 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
1991
Active, not recruiting
19
5.9%
Completed
170
53.1%
Not yet recruiting
9
2.8%
Recruiting
37
11.6%
Terminated
65
20.3%
Withdrawn
20
6.3%
No approval data available
- A new study in Nature Immunology challenges the decades-old paradigm that MHC class I exclusively mediates CD8+ T cell responses, revealing a previously unrecognized role in CD4+ T cell immunity. - Researchers found that when cancer cells downregulate MHC I to evade killer T cells, they paradoxically become more susceptible to CD4+ helper T cell-mediated destruction via ferroptosis. - The findings, validated in both mouse models and human clinical datasets from checkpoint inhibitor-treated patients, show correlations between this mechanism and patient outcomes. - The discovery may enable novel immunotherapies that target MHC class I and CD4+ T cells, with potential applications beyond oncology including graft-versus-host disease and autoimmune conditions.
- Genprex's Reqorsa gene therapy demonstrated a 79% tumor reduction in ALK-positive non-small cell lung cancer models during preclinical studies presented at the 2025 AACR-NCI-EROTC Conference. - The combination of Reqorsa with alectinib improved treatment outcomes by 23% compared to alectinib alone, suggesting potential as a companion therapy for advanced disease. - The positive preclinical data supports the advancement of Reqorsa toward clinical trials for ALK-EML4 positive NSCLC, a subset that primarily affects young, non-smoking individuals. - Laboratory studies show that Reqorsa's TUSC2 gene uptake in tumor cells was 10 to 33 times higher than in normal cells, demonstrating selective cancer cell targeting.
